FY2025 · ended Dec 31, 2025 · Revenue $109.79M, +21.4% YoY · Filed Mar 2, 2026
UroGen Pharma Ltd. (URGN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $109.8 million and a net loss of $153.5 million. Free cash flow was -$162.7 million. As of Sep 30, 2026 it held $91.9 million in cash and investments and $206.9 million in total debt.
Revenue (TTM)
$250.25M
+159.3% vs year-ago TTM
Net income (TTM)
$-65.75M
+60.1% vs year-ago TTM
Operating cash flow (TTM)
$-131.85M
+4.3% vs year-ago TTM
Free cash flow (TTM)
$-132.05M
+4.4% vs year-ago TTM
EPS
—
Dividend per share
None
Shares outstanding
48.68M
+5.6% vs prior year
Net cash
$-115.01M
as of Sep 30, 2026
Operating margin
-12.4%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- URGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Ra'Anana, Israel
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1668243
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $109.8M | $90.4M | $82.7M | $64.4M | $48.0M |
| Operating income | -$124.9M | -$96.8M | -$65.5M | -$79.0M | -$92.3M |
| Net income | -$153.5M | -$126.9M | -$102.2M | -$109.8M | -$110.8M |
| Operating cash flow | -$162.4M | -$96.8M | -$76.4M | -$87.6M | -$84.9M |
| Free cash flow | -$162.7M | -$97.1M | -$76.6M | -$87.8M | -$85.6M |
| Total assets | $200.5M | $285.7M | $178.3M | $135.6M | $119.7M |
| Total liabilities | $305.9M | $294.5M | $243.5M | $225.0M | $111.3M |
| Stockholders' equity | -$105.5M | -$8.8M | -$65.2M | -$89.4M | $8.4M |
| Cash and investments | $160.1M | $287.7M | $155.7M | $100.0M | $89.8M |
| Total debt | $132.9M | $124.9M | $100.2M | $100.1M | $1.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Other events
|
Aug 20, 2026 | Aug 18, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Change to shareholder rights, Officer or director change, Shareholder vote results
|
Jun 23, 2026 | Jun 22, 2026 |
All 583 UroGen Pharma Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.